Close Menu

NEW YORK (GenomeWeb) – Affymetrix and UK-based XRGenomics are collaborating on the development of new diagnostic tests for neurodegenerative diseases, the companies said today.

Financial and other terms of the agreement were not disclosed.

XRGenomics has used Affymetrix's GeneTitan microarray technology to develop gene expression signatures and find biomarkers for diseases such as Alzheimer's disease.

The firm plans to use the technology to optimize its RNA signatures in large clinical trials involving thousands of patients with cognitive impairment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.